NasdaqCM:OVIDBiotechs
A Look At Ovid Therapeutics (OVID) Valuation After OV329 Trial Update And US$60 Million Financing
Ovid Therapeutics (OVID) has drawn fresh attention after reporting Phase 1 data for its OV329 epilepsy program at a 7 mg dose, alongside plans to expand into new seizure indications backed by about US$60 million in private financing.
See our latest analysis for Ovid Therapeutics.
The new OV329 data and US$60 million financing arrive after a sharp run in the stock, with a 30 day share price return of 60.84% and a 1 year total shareholder return above 400%, even though the 3 year and 5 year...